Neuroproteomics: Relevance to anxiety disorders

Current Psychiatry Reports

Volumn 8, Issue 4, 2006, Pages 286-290

  Uys, Joachim D K ^a   Stein, Dan J ^b   Daniels, Willie M U ^c  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 MICROGLOBULIN; AMYLOID PRECURSOR PROTEIN; BRAIN PROTEIN; FLUOXETINE; FRUCTOSE BISPHOSPHATE ALDOLASE; GLIA MATURATION FACTOR; GLIAL FIBRILLARY ACIDIC PROTEIN; HEAT SHOCK PROTEIN 10; LACTOYLGLUTATHIONE LYASE; MEMBRANE RECEPTOR; NEUROTRANSMITTER; PROTEOME; SOMATOMEDIN; VENLAFAXINE;

ACCURACY; ALZHEIMER DISEASE; AMYGDALOID NUCLEUS; ANXIETY DISORDER; CHRONIC FATIGUE SYNDROME; COMPUTER PROGRAM; DEPRESSION; DNA MICROARRAY; DRUG MECHANISM; ELECTROSPRAY MASS SPECTROMETRY; ENERGY METABOLISM; FIBROMYALGIA; GENE CONTROL; GENE EXPRESSION; HIGH THROUGHPUT SCREENING; HIPPOCAMPUS; HUMAN; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOTOR CORTEX; NERVE CELL PLASTICITY; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PERSIAN GULF SYNDROME; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; QUANTITATIVE ANALYSIS; REVIEW; SCHIZOPHRENIA; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION; TWO DIMENSIONAL ELECTROPHORESIS; TWO DIMENSIONAL GEL ELECTROPHORESIS; UPREGULATION;

ANIMALS; ANXIETY DISORDERS; BRAIN; DISEASE MODELS, ANIMAL; ELECTROPHORESIS; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; ISOTOPE LABELING; MENTAL DISORDERS; PROTEOMICS;

EID: 33747180876     PISSN: 15233812     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11920-006-0064-5     Document Type: Review

References (48)

1. Kessler RC, Demler O, Frank RG, et al.: Prevalence and treatment of mental disorders, 1990 to 2003. N Engl J Med 2005, 352:2515-2523.
2. Stein DJ, Hollander E: Textbook of Anxiety Disorders. Washington, DC: American Psychiatric Press; 2002.
3. Zarate CA, Jr, Singh J, Manji HK: Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorder. Biol Psychiatry 2006 [Epub ahead of print].
4. Gould TD, Manji HK: The molecular medicine revolution and psychiatry: bridging the gap between basic neuroscience research and clinical psychiatry. J Clin Psychiatry 2004, 65:598-604.
5. Bachmann RF, Schloesser RJ, Gould TD, et al.: Mood stabilizers target cellular plasticity and resilience cascades: implications for the development of novel therapeutics. Mol Neurobiol 2005, 32:173-202.
6. Lesch KP, Hough CJ, Aulakh CS, et al.: Fluoxetine modulates G protein alpha s, alpha q, and alpha 12 subunit mRNA expression in rat brain. Eur J Pharmacol 1992, 227:233-237.
7. Stein LD: Human genome: end of the beginning. Nature 2004, 431:915-916.
8. Aebersold R, Goodlett DR: Mass spectrometry in proteomics. Chem Rev 2001, 101:269-295.
9. Blackstock WP, Weir MP: Proteomics: quantitative and physical mapping of cellular proteins. Trends Biotechnol 1999, 17:121-127.
10. Conrads TP, Anderson GA, Veenstra TD, et al.: Utility of accurate mass tags for proteome-wide protein identification. Anal Chem 2000, 72:3349-3354.
11. Choudhary J, Grant SG: Proteomics in postgenomic neuroscience: the end of the beginning. Nat Neurosci 2004, 7:440-445.
12. Cantin GT, Yates JR 3rd: Strategies for shotgun identification of post-translational modifications by mass spectrometry. J Chromatogr A 2004, 1053:7-14.
13. Grant SG, Blackstock WP: Proteomics in neuroscience: from protein to network. J Neurosci 2001, 21:8315-8318.
14. Blagoev B, Ong SE, Kratchmarova I, et al.: Temporal analysis of phosphotyrosine-dependent signaling networks by quantitative proteomics. Nat Biotechnol 2004, 22:1139-1145.
15. Lane CS: Mass spectrometry-based proteomics in the life sciences. Cell Mol Life Sci 2005, 62:848-869.
16. Mitulovic G, Stingl C, Smoluch M, et al.: Automated, on-line two-dimensional nano liquid chromatography tandem mass spectrometry for rapid analysis of complex protein digests. Proteomics 2004, 4:2545-2557.
17. Maurer MH, Berger C, Wolf M, et al.: The proteome of human brain microdialysate. Proteome Sci 2003, 1:7.
18. Tonge R, Shaw J, Middleton B, et al.: Validation and development of fluorescence two-dimensional differential gel electrophoresis proteomics technology. Proteomics 2001, 1:377-396.
19. Lilley KS, Friedman DB: All about DIGE: quantification technology for differential-display 2D-gel proteomics. Expert Rev Proteomics 2004, 1:401-409.
20. Zhou G, Li H, DeCamp D, et al.: 2D differential in-gel electrophoresis for the identification of esophageal scans cell cancer-specific protein markers. Mol Cell Proteomics 2002, 1:117-124.
21. Witzmann FA, Arnold RJ, Bai F, et al.: A proteomic survey of rat cerebral cortical synaptosomes. Proteomics 2005, 5:2177-2201.
22. Bunai K, Yamane K: Effectiveness and limitation of two-dimensional gel electrophoresis in bacterial membrane protein proteomics and perspectives. J Chromatogr B Analyt Technol Biomed Life Sci 2005, 815:227-236.
23. Wu CC, Yates JR 3rd: The application of mass spectrometry to membrane proteomics. Nat Biotechnol 2003, 21:262-267.
24. Hansen KC, Schmitt-Ulms G, Chalkley RJ, et al.: Mass spectrometric analysis of protein mixtures at low levels using cleavable 13C-isotope-coded affinity tag and multi-dimensional chromatography. Mol Cell Proteomics 2003, 2:299-314.
25. Ross PL, Huang YN, Marchese JN, et al.: Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol Cell Proteomics 2004, 3:1154-1169.
26. Shadforth IP, Dunkley TP, Lilley KS, Bessant C: i-Tracker: for quantitative proteomics using iTRAQ. BMC Genomics 2005, 6:145.
27. Kowalski P, Stoerker J: Accelerating discoveries in the proteome and genome with MALDI TOF MS. Pharmacogenomics 2000, 1:359-366.
28. Pusch W, Kostrzewa M: Application of MALDI-TOF mass spectrometry in screening and diagnostic research. Curr Pharm Des 2005, 11:2577-2591.
29. Ginter JM, Zhou F, Johnston MV: Generating protein sequence tags by combining cone and conventional collision induced dissociation in a quadrupole time-of-flight mass spectrometer. J Am Soc Mass Spectrom 2004, 15:1478-1486.
30. Elias JE, Haas W, Faherty BK, Gygi SP: Comparative evaluation of mass spectrometry platforms used in large-scale proteomics investigations. Nat Methods 2005, 2:667-675.
31. Medzihradszky KF, Campbell JM, Baldwin MA, et al.: The characteristics of peptide collision-induced dissociation using a high-performance MALDI-TOF/TOF tandem mass spectrometer. Anal Chem 2000, 72:552-558.
32. Pan S, Zhang H, Rush J, et al.: High throughput proteome screening for biomarker detection. Mol Cell Proteomics 2005, 4:182-190.
33. Liu Z, Schey KL: Optimization of a MALDI TOF-TOF mass spectrometer for intact protein analysis. J Am Soc Mass Spectrom 2005, 16:482-490.
34. Sadygov RG, Cociorva D, Yates JR 3rd: Large-scale database searching using tandem mass spectra: looking up the answer in the back of the book. Nat Methods 2004, 1:195-202.
35. Carboni L, Piubelli C, Pozzato C, et al.: Proteomic analysis of rat hippocampus after repeated psychosocial stress. Neuroscience 2006, 137:1237-1246.
36. Fukudo S, Abe K, Itoyama Y, et al.: Psychophysiological stress induces heat shock cognate protein 70 messenger RNA in the hippocampus of rats. Neuroscience 1999, 91:1205-1208.
37. Kromer SA, Kessler MS, Milfay D, et al.: Identification of glyoxalase-I as a protein marker in a mouse model of extremes in trait anxiety. J Neurosci 2005, 25:4375-4384.
38. Chen F, Wollmer MA, Hoerndli F, et al.: Role for glyoxalase I in Alzheimer's disease. Proc Natl Acad Sci U S A 2004, 101:7687-7692.
39. Tanna VL, Wilson AF, Winokur G, et al.: Linkage analysis of pure depressive disease. J Psychiatr Res 1989, 23:99-107.
40. Uys JD, Stein DJ, Daniels WM, et al.: Animal models of anxiety disorders. Curr Psychiatry Rep 2003, 5:274-281.
41. Khawaja X, Xu J, Liang JJ, et al.: Proteomic analysis of protein changes developing in rat hippocampus after chronic antidepressant treatment: implications for depressive disorders and future therapies. J Neurosci Res 2004, 75:451-460.
42. Tomitaka M, Tomitaka S, Rajdev S, et al.: Fluoxetine prevents PCP- and MK801-induced HSP70 expression in injured limbic cortical neurons of rats. Biol Psychiatry 2000, 47:836-841.
43. Kim SI, Voshol H, van Oostrum J, et al.: Neuroproteomics: expression profiling of the brain's proteomes in health and disease. Neurochem Res 2004, 29:1317-1331.
44. Johnston-Wilson NL, Sims CD, Hofmann JP, et al.: Disease-specific alterations in frontal cortex brain proteins in schizophrenia, bipolar disorder, and major depressive disorder. The Stanley Neuropathology Consortium. Mol Psychiatry 2000, 5:142-149.
45. Baraniuk JN, Casado B, Maibach H, et al.: A chronic fatigue syndrome - related proteome in human cerebrospinal fluid. BMC Neurol 2005, 5:22.
46. Segman RH, Shefi N, Goltser-Dubner T, et al.: Peripheral blood mononuclear cell gene expression profiles identify emergent post-traumatic stress disorder among trauma survivors. Mol Psychiatry 2005, 10:500-513.
47. Nielsen PA, Olsen JV, Podtelejnikov AV, et al.: Proteomic mapping of brain plasma membrane proteins. Mol Cell Proteomics 2005, 4:402-408.
48. Stephan C, Reidegeld K, Meyer HE, Hamacher M: HUPO Brain Proteome Project Pilot Studies: bioinformatics at work. Proteomics 2005, 5:2716-2717.